World Journal of *Meta-Analysis*

World J Meta-Anal 2023 September 18; 11(6): 253-312





Published by Baishideng Publishing Group Inc

WJMA

World Journal of **Meta-Analysis**

Contents

Quarterly Volume 11 Number 6 September 18, 2023

REVIEW

253 Overview of angiogenesis and oxidative stress in cancer

> Andriolo LG, Cammisotto V, Spagnoli A, Alunni Fegatelli D, Chicone M, Di Rienzo G, Dell'Anna V, Lobreglio G, Serio G, Pignatelli P

History, origin, transmission, genome structure, replication, epidemiology, pathogenesis, clinical features, 266 diagnosis, and treatment of COVID-19: A review

Mokhria RK, Bhardwaj JK, Sanghi AK

META-ANALYSIS

- 277 Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis dos Santos ESV, de Oliveira GHP, de Moura DTH, Hirsch BS, Trasolini RP, Bernardo WM, de Moura EGH
- 290 Evidence relating cigarettes, cigars and pipes to cardiovascular disease and stroke: Meta-analysis of recent data from three regions

Lee PN, Coombs KJ, Hamling JS



Contents

Quarterly Volume 11 Number 6 September 18, 2023

ABOUT COVER

Editorial Board Member of World Journal of Meta-Analysis, Cheng Lan, MD, PhD, Chief Doctor, Professor, Department of Gastroenterology, Hainan General Hospital, Affiliated Hainan Hospital, Hainan Medical University, Haikou 570311, Hainan Province, China. lancheng71@163.com

AIMS AND SCOPE

The primary aim of World Journal of Meta-Analysis (WJMA, World J Meta-Anal) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality meta-analysis and systematic review articles and communicate their research findings online.

WJMA mainly publishes articles reporting research results and findings obtained through meta-analysis and systematic review in a wide range of areas, including medicine, pharmacy, preventive medicine, stomatology, nursing, medical imaging, and laboratory medicine.

INDEXING/ABSTRACTING

The WJMA is now abstracted and indexed in Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Meta-Analysis	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2308-3840 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
May 26, 2013	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Quarterly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Saurabh Chandan, Jing Sun	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2308-3840/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
September 18, 2023	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



WJM

World Journal of **Meta-Analysis**

Submit a Manuscript: https://www.f6publishing.com

World J Meta-Anal 2023 September 18; 11(6): 277-289

DOI: 10.13105/wjma.v11.i6.277

ISSN 2308-3840 (online)

META-ANALYSIS

Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis

Evellin Souza Valentim dos Santos, Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Bruno Salomão Hirsch, Roberto Paolo Trasolini, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): 0 Grade C (Good): C Grade D (Fair): D Grade E (Poor): 0

P-Reviewer: Homan M, Slovenia; Konishi H, Japan

Received: February 28, 2023 Peer-review started: February 28, 2023 First decision: March 24, 2023 Revised: May 17, 2023 Accepted: June 16, 2023 Article in press: June 16, 2023 Published online: September 18, 2023



Evellin Souza Valentim dos Santos, Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Bruno Salomão Hirsch, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura, Department of Gastroenterology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, Brazil

Roberto Paolo Trasolini, Department of Gastroenterology and Hepatology, Hospital Harvard Medical School, Boston, MA 02115, United States

Corresponding author: Guilherme Henrique Peixoto de Oliveira, MD, Medical Assistant, Department of Gastroenterology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr Enéas de Carvalho Aguiar, 225, São Paulo 05403-010, Brazil. guilherme.hpoliveira@hc.fm.usp.br

Abstract

BACKGROUND

Percutaneous endoscopic gastrostomy (PEG) and percutaneous radiological gastrostomy (PRG) are minimally invasive techniques commonly used for prolonged enteral nutrition. Despite safe, both techniques may lead to complications, such as bleeding, infection, pain, peritonitis, and tube-related complications. The literature is unclear on which technique is the safest.

AIM

To establish which approach has the lowest complication rate.

METHODS

A database search was performed from inception through November 2022, and comparative studies of PEG and PRG were selected following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. All included studies compared the two techniques directly and provided absolute values of the number of complications. Studies with pediatric populations were excluded. The primary outcome of this study was infection and bleeding. Pneumonia, peritonitis, pain, and mechanical complications were secondary outcomes. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB2) and we used The Risk of Bias in Nonrandomized Studies (ROBINS-I) to analyze the retrospective studies. We also performed GRADE analysis to assess the quality of evidence. Data on risk differences and



95% confidence intervals were obtained using the Mantel-Haenszel test.

RESULTS

Seventeen studies were included, including two randomized controlled trials and fifteen retrospective cohort studies. The total population was 465218 individuals, with 273493 having undergone PEG and 191725 PRG. The only outcome that showed a significant difference was tube related complications in retrospective studies favoring PEG (95% CI: 0.03 to 0.08; P < 0.00001), although this outcome did not show significant difference in randomized studies (95% CI: -0.07 to 0.04; P = 0.13). There was no difference in the analyses of the following outcomes: infection in retrospective (95%CI: -0.01 to 0.00; P < 0.00001) or randomized (95%CI: -0.06 to 0.04; P = 0.44) studies; bleeding in retrospective (95% CI: -0.00 to 0.00; P < 0.00001) or randomized (95% CI: -0.06 to 0.02; P = 0.43) studies; pneumonia in retrospective (95%CI: -0.04 to 0.00; P = 0.28) or randomized (95%CI: -0.09 to 0.11; P = 0.39) studies; pain in retrospective (95%CI: -0.05 to 0.02; P < 0.00001) studies; peritonitis in retrospective (95%CI: -0.02 to 0.01; P < 0.0001) studies.

CONCLUSION

PEG has lower levels of tube-related complications (such as dislocation, leak, obstruction, or breakdown) when compared to PRG.

Key Words: Gastrostomy; Adverse events; Meta-analysis; Percutaneous endoscopic; Radiological gastrostomy

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Gastrostomy is a routine and preferred feeding route in patients who require enteral nutrition for prolonged period. This metanalysis compared percutaneous endoscopic gastrostomy and percutaneous radiological gastrostomy multiple outcomes, such as bleeding, infection, pneumonia, pain, and tube-related complications. Based on this meta-analysis, gastrostomy technique is related to a lower complication rate of tube-related complications and thus, should be preferred. Costs, devices availability, personal and local experience as well as patients preference should be considered when choose the best technique.

Citation: dos Santos ESV, de Oliveira GHP, de Moura DTH, Hirsch BS, Trasolini RP, Bernardo WM, de Moura EGH. Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis. World J Meta-Anal 2023; 11(6): 277-289 URL: https://www.wjgnet.com/2308-3840/full/v11/i6/277.htm DOI: https://dx.doi.org/10.13105/wjma.v11.i6.277

INTRODUCTION

Patients unable to tolerate oral intake for a prolonged period have an indication for an alternative route of enteral feeding, such as gastrostomy[1]. Gastrostomy involves connecting the stomach to an outflow in the skin with a tube, providing an alimentary route.

The first gastrostomy was performed in the 19th century, and Stamm's technique, surgical gastrostomy described in 1894, was long considered standard for performing a prolonged enteric access. The surgical technique became less performed with the emergence of the endoscopic technique. The method of percutaneous endoscopic gastrostomy (PEG) was first used in 1980 by Gauderer and Ponsky[2]. The technique was developed as a minimally invasive feeding route for neurologically impaired patients.

In 1981, percutaneous radiologic gastrostomy (PRG) was described^[3], expanding the options available. This was an important development for scenarios such as head and neck tumors, where endoscopy is sometimes not an option, due to upper obstruction.

Endoscopic and radiological gastrostomy are both considered effective, safe and minimally invasive[4,5]. The preferred method is often based on specialist opinion or institution preference. We aim to perform a systematic review of the literature and meta-analysis to establish which approach has the lowest complication rate.

MATERIALS AND METHODS

Protocol and registration

This study was performed in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines^[6] and was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the file number CRD42022377213.



Information source and literature search

The electronic databases searched were MEDLINE (via PubMed), Embase, Scopus, LILACS, the Cochrane Library (via BVS), and Google Scholar from inception until November 2022. The search was performed with the following mesh terms: [(Gastrostomy or Gastrostomies) and (Endoscopic)].

Eligibility criteria

The selection criteria were studies that contained patients undergoing gastrostomy, that compared the two interventions (PEG and PRG) and that included the following outcomes: Bleeding, infection, pain, peritonitis, tube-related complications with their results in absolute values.

Eligibility assessment was performed independently and standardized by 2 authors according to PRISMA guidelines [6]. Discrepancies between reviewers were resolved by consensus. A third reviewer was consulted in case of disagreements.

Case reports, reviews and letters were excluded. Studies that exclusively analyzed patients under 18 years of age, compared other techniques or did not consider the desired outcomes were excluded. Studies with the pediatric population were excluded because of anatomical differences with the adult population and consequently different complications.

To assess the quality of eligible studies we used The Risk of Bias in Nonrandomized Studies (ROBINS-I)[7] to analyze the comparative studies and the Cochrane risk-of-bias tool for randomized trials (RoB2)[8] to analyze the randomized studies. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria using the GRADE pro Guideline Development Tool software (Mc Master University, Ontario, Canada)[9].

Data analyses

The randomized controlled trials (RCT) studies were analyzed separately from the observational studies since they have different levels of evidence. This allowed us to compare the outcomes separately and to make a global analysis of the results.

The analysis was performed using Review Manager (RevMan 5.4) from the Cochrane Informatics & Knowledge Management Department website. Risk differences for dichotomous variables were computed using a fixed-effects model and the respective forest and funnel plots were obtained. Data on risk differences and the 95% confidence intervals (CI) for each outcome were calculated using the Mantel-Haenszel test. Inconsistency (heterogeneity) was qualified and reported using the Chi-squared (Chi²) and Higgins methods and was termed l^2 . l^2 values > 50% were considered to indicate substantial heterogeneity. We performed an analysis using a funnel plot to identify possible outliers. If the sample became homogeneous after excluding possible outliers, the studies were permanently excluded. We used random effects to reduce the influence of heterogeneity on the final result[10]. Outcome measures are described as the mean difference or risk difference (RD), with their corresponding 95%CI.

RESULTS

The initial search showed 15585 results, after removing the duplicate articles, 6490 remained. A total of twenty studies passed the screening stage and were included in qualitative synthesis, seventeen studies met criteria to be included in the metanalysis, two were prospective randomized studies and fifteen were retrospective cohort studies. The search strategy can be visualized in the following diagram (Figure 1).

Study characteristics

Seventeen studies were included in the systematic review, including two RCTs, one prospective, and 14 retrospective cohort studies. A total of 465218 individuals, with 273493 received PEG and 191725 PRG. The characteristics of the studies can be seen in Table 1[11-27]. Early outcomes were analyzed.

Risk of bias within studies

The ROBINS-I and ROB-2 scoring system were used to evaluate risk of bias for observational [12-18,20-27] and randomized studies[11,19], respectively (Table 1). We identified a low risk of bias in the two RCT studies (Figure 2), and a strong methodological quality. As for the observational studies, we note that 5 of them present serious risk of bias[13,15, 25,27] and 5 moderate risk[12,14,18,21,23], mostly due to issues in the dissemination of results (Figure 3).

Quality of evidence

The objective criteria of GRADE analysis to evaluate the quality of evidence identified moderate certainty for pain and infection, low certainty for peritonitis and very low certainty for bleeding and pneumonia (Figure 4).

Infection

A total of 465198 patients from 17 studies [12-27] were analyzed. There was no difference in the incidence of infection in retrospective (95%CI: -0.01 to 0.00; P < 0.00001; $I^2 = 74\%$) or randomized (95%CI: -0.06 to 0.04; P = 0.68; $I^2 = 0\%$) studies. In the overall analysis there was no difference in the meta-analysis of observational and RCT studies combined (95% CI: -0.01 to 0.00; P = 0.56; $I^2 = 70\%$) (Figure 5A).



Table 1 Early outcomes were analyzed										
Ref.	Country	Design	Period	PEG (N)	RIG (N)	Mean age PEG	Mean age RIG	Single (S) or Multicenter (M)		
Hoffer <i>et al</i> [11], 1999	United States	Randomized	1993- 1994	69	66	58.2	51.9	S		
Möller <i>et al</i> [12], 1999	Sweden	Retrospective	1990- 1994	12	94	48	64	S		
Laasch <i>et al</i> [<mark>13</mark>], 2002	United Kingdom	Prospective	2000- 2002	50	50	73	68	M (3)		
Silas <i>et al</i> [14] , 2005	United States	Retrospective	1997- 2001	177	193	68	63	S		
Rustom <i>et al</i> [15], 2006	United Kingdom	Retrospective	2002- 2005	40	28	63.6	64.8	S		
Galaski <i>et al</i> [<mark>16</mark>], 2009	Canada	Retrospective	2004- 2005	30	44	55	65	S		
La Nauze <i>et al</i> [17], 2012	Australia	Retrospective	2007- 2009	80	97	61	61	S		
Rio <i>et al</i> [18] , 2010	United Kingdom	Retrospective	1999- 2006	21	122	64	64	S		
Lewis <i>et al</i> [19], 2014	United Kingdom	Randomized	2012- 2013	34	31	73	71	S		
ProGas Study Group[20], 2015	United Kingdom	Retrospective	2010- 2014	121	163	64.2	63.6	M (24)		
Vidhya <i>et al</i> [<mark>21</mark>], 2018	Australia	Retrospective	2013- 2015	85	52	65	64	S		
Park <i>et al</i> [22], 2019	South Korea	Retrospective	2010- 2015	324	94	66	66.2	M (5)		
Strijbos <i>et al</i> [23], 2019	Netherlands	Retrospective	2008- 2016	291	469	66	66.2	S		
Lainez <i>et al</i> [24], 2020	Spain	Retrospective	2019	25	23	63.98	62.41	S		
Maasarani <i>et al</i> [25], 2020	United States	Retrospective	2004- 2014	232164	26477	NI	NI	М		
Kohli <i>et al</i> [26] , 2020	United States	Retrospective	2014- 2017	16384	154007	53.7	67.2	М		
Kohli <i>et al</i> [27], 2021	United States	Retrospective	2011- 2021	23566	9715	70.7	69.6	М		

PEG: Percutaneous endoscopic gastrostomy; PRG: Radiologically guided gastrostomy; NI: Not informed.

Bleeding

A total of 464618 patients from fourteen[11-13,16,17,19-27] studies were analyzed. There was no difference in the incidence of bleeding in observational studies (95% CI: -0.00 to 0.00; P < 0.00001; P = 76%) or RCTs (95% CI: -0.06 to 0.02; P = 0.43; $I^2 = 0\%$). In the overall analysis there was no difference in the meta-analysis of observational and RCT studies combined (95% CI: -0.00 to 0.00); P = 0.81; $I^2 = 73\%$) (Figure 5B).


Pneumonia


A total of 1796 patients from eight[11,13,17,19-21,23,24] studies were analyzed. There was no difference in the incidence of pneumonia in comparative studies (95%CI: -0.00 to 0.04; P = 0.28; $l^2 = 20\%$) or RCT (95%CI: -0.10 to 0.10; P = 0.39; $l^2 = 0\%$) studies. In the overall analysis there was no difference in the meta-analysis of observational and RCT studies combined (95%CI: -0.00 to 0.03; P = 0.44; $l^2 = 0\%$) (Figure 5C).

Peritonitis

A total of 34461 patients from five[12,17,21,23,27] were analyzed. There was no difference in the incidence of peritonitis in retrospective (95% CI: -0.02 to 0.01; P < 0.0001; P = 86%) studies. It was not possible to evaluate the peritonitis outcome in RCT studies because this outcome was not included in these studies (Figure 5D).

Raishideng® WJMA https://www.wjgnet.com








Figure 2 Risk of bias according to ROB-2.

Pain

A total of 260793 patients from seven[14,17,18,20,22,23,25] studies were analyzed. There was no difference in the incidence of pain in retrospective (95% CI: -0.05 to 0.02; P < 0.00001; $I^2 = 91\%$) studies. It was not possible to evaluate the pain outcome in RCT studies because this outcome was not included in these studies (Figure 5E).

Tube related complications

A total of 464689 patients from 14 studies [11-19,21-23,25,26] were analyzed. This analysis showed a significant difference in tube related complications in observational studies favoring PEG (95%CI: -0.03 to -0.08; P < 0.00001), although there was no significant difference in randomized studies (95%CI: -0.07 to 0.04; P = 0.13). In the global analysis there was a difference, favoring PEG (95%CI: -0.07 to -0.03; P < 0.00001) (Figure 6).




Figure 3 Risk of bias according to ROBINS-I.

		Certainty a	issessment	N° of pa	atients	Effec				
Study desing	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pain	Placebo	Relative (95% CI)	Absolute (95% Cl)	Certainty
observational studies	not serious	not serious	serious	not serious	none	12230/27573 (44.4%)	96205/233220 (41.3%)	RR 1.11 (1.09 to 1.12)	45 more per 1.000 (from 37 more to 50 more)	Moderate
observational studies	not serious	serious	not serious	not serious	none	2226/191683 (1.2%)	3171/273515 (1.2%)	RR 1.10 (0.87 to 1.38)	1 more per 1.000 (from 2 fewer to 4 more)	Moderate
observational studies	not serious	not serious	not serious	not serious	none	28/10427 (0.3%)	455/24034 (1.9%)	RR 0.54 (0.11 to 2.56)	9 fewer per 1.000 (from 17 fewer to 30 more)	
observational studies	not serious	serious	not serious	not serious	none	785/191277 (0.4%)	973/273206 (0.4%)	RR 1.16 (0.69 to 1.95)	1 more per 1.000 (from 1 fewer to 3 more)	€©©© Very low
observational studies	serious	not serious	not serious	not serious	none	28/909 (3.1%)	39/797 (4.9%)	RR 0.72 (0.46 to 1.14)	14 fewer per 1.000 (from 26 fewer to 7 more)	● © © © Very low
	desing observational studies observational studies observational studies observational studies	desing Risk of Dias observational studies not serious observational studies not serious observational studies not serious observational studies not serious	Study desing Risk of bias Inconsistency observational studies not serious not serious observational studies not serious serious observational studies not serious serious observational studies not serious serious	Study desing Risk of bias Inconsistency Indirectness observational studies not serious not serious serious observational studies not serious serious not serious observational studies not serious serious not serious observational studies not serious not serious not serious observational studies not serious serious not serious	Study desing Risk of bias Inconsistency Indirectness Imprecision observational studies not serious not serious serious not serious observational studies not serious serious not serious not serious	Study desing Risk of bias Inconsistency Indirectness Imprecision Other considerations observational studies not serious not serious serious not serious none observational studies not serious serious not serious not serious none observational studies not serious serious not serious not serious none observational studies not serious not serious not serious not serious none observational studies not serious serious not serious not serious not serious none	Study desing Risk of blas Inconsistency Indirectness Imprecision Other considerations Pain observational studies not serious not serious serious not serious<	Study desing Risk of blas Inconsistency Indirectness Imprecision Other considerations Pain Placebo observational studies not serious not serious serious not serious not serious not serious 96205/233220 (41.3%) observational studies not serious serious not serious not serious not serious not serious 12230/27573 (44.4%) 96205/233220 (41.3%) observational studies not serious serious not serious not serious not serious not serious 3171/273515 (1.2%) observational studies not serious 12210/27 (0.3%) 455/24034 (1.9%) observational studies not serious serious not serious not serious not serious none 785/191277 (0.4%) 973/273206 (0.4%) observational studies not serious serious not serious not serious none 785/191277 (0.4%) 973/273206 (0.4%)	Study desing Risk of blas Inconsistency Indirectness Imprecision Other considerations Pain Placebo Relative (95% Cl) observational studies not serious not serious serious not seriou	Study desing Risk of bias Inconsistency Indirectness Imprecision Other considerations Pain Placebo Relative (95% CI) Absolute (95% CI) observational studies not serious not serious serious not

Figure 4 Quality of evidence assessed by Grading of Recommendations Assessment, Development, and Evaluation.

DISCUSSION

This meta-analysis shows that both PEG and PRG techniques are similar in terms of safety profile, except potentially in tube-related complications, which was higher for PRG in observational studies (Evidence 2A). We included 20 studies in this review (3 randomized and 17 comparative studies) and 17 in our meta-analysis, totaling 465218 individuals, with 273493 undergoing PEG and 191725 undergoing PRG. While other metanalyses compared these 2 approaches[28-34], this analysis is unique as it includes the largest number of adult patients and also separates RCT and observational studies providing further insight. This approach follows Cochrane recommendations and thus provides for a more reliable



Baishidena® WJMA https://www.wjgnet.com

A	PE		RI			Risk difference	Risk diffe	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Randon	n, 95% Cl
1.1.1 OBSERVATION	AL							
1999 Moller	0	12	1	94	0.2%	-0.01 [-0.12 , 0.10]	←	
2002 Laasch	9	50	1	50	0.1%	0.16 [0.05 , 0.27]		+
2005 Silas	14	177	3	193	0.9%	0.06 [0.02 , 0.11]		→
2006 Rustom	4	40	6	28	0.1%	-0.11 [-0.29 , 0.06]	← →	
2009 Galaski	2	30	2	44	0.2%	0.02 [-0.09 , 0.13]	• – – – – – – – – – – – – – – – – – – –	,
2010 Rio	2	21	17	122	0.1%	-0.04 [-0.18 , 0.10]	•	,
2012 La Nauze	11	80	13	97	0.2%	0.00 [-0.10 , 0.10]	•	,
2015 McDermott	20	163	21	121	0.3%	-0.05 [-0.14 , 0.03]	•	
2018 Vidhya	9	85	7	52	0.1%	-0.03 [-0.14 , 0.08]		,
2019 Park	18	324	2	94	1.2%	0.03 [-0.00 , 0.07]	`	
2019 Strijbos	5	291	7	469	4.5%	0.00 [-0.02 , 0.02]		
2020 Kohli	142	16384	1587	154007	30.9%	-0.00 [-0.00 , -0.00]		
2020 Lainez	1	25	0	23	0.2%	0.04 [-0.07 , 0.15]	. 1	
2020 Maasarani	2734	232164	475	26477	30.6%	-0.01 [-0.01 , -0.00]	·	
2021 Kohli	197	23566	79	9715	29.7%	0.00 [-0.00 , 0.00]	•	
Subtotal (95%CI)	131	273412	15	191586	99.2%		1	
Total events:	3168	2/3412	2221	191300	33.2 /0	-0.00 [-0.01 , 0.00]	•	
		- 52 09		< 0.0000	1): 12 - 74	0/		
leterogeneity: Tau ² =			ui – 14 (<i>P</i>	< 0.0000	1), 1 - 74	70		
est for overall effect:	2 - 0.52 (/	- 0.60)						
1 2 8 6 7								
.1.2 RCT	~	~~~	-		0.001	0.001.0.01		
999 Hoffer	3	69	5	66	0.3%	-0.03 [-0.11 , 0.05]	←	
014 Lewis	0	34	0	31	0.5%	0.00 [-0.06 , 0.06]	•	
Subtotal (95%CI)		103	_	97	0.8%	-0.01 [-0.06 , 0.04]		
otal events:	3		5					
leterogeneity: Tau ² =			f = 1 (<i>P</i> =	0.44); l² =	0%			
est for overall effect:	Z = 0.47 (/	P = 0.64)						
otal (95%CI)		273515		191683	100.0%	-0.00 [-0.01 , 0.00]	•	
fotal events:	3171		2226					
Heterogeneity: Tau ² =	= 0.00; Chi ²	= 53.71, (df = 16 (<i>P</i>	< 0.0000	1); I ² = 70	%	-0.05 -0.025 0	0.025 0.
Test for overall effect:							Favours (PEG)	Favours (RIG
Test for subgroup diff	erences: Ch	$ni^2 = 0.17$	df = 1 (P)	-069) 1				
		0.17	ui – i (/-	- 0.00), 1	² = 0%			
3	PE		RI		² = 0%	Risk difference	Risk diffe	erence
						Risk difference M-H, Random, 95%Cl	Risk diffe M-H, Rando	
tudy or Subgroup	PE	G	RI	G				
tudy or Subgroup .2.1 Observational	PE Events	G Total	Rie Events	G Total	Weight	M-H, Random, 95% Cl	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller	PE Events 2	G Total 94	RIG Events	G Total 12	Weight 0.1%	M-H, Random, 95% Cl 0.02 [-0.09 , 0.13]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch	PE Events 2 0	G Total 94 50	Ric Events	G Total 12 50	Weight 0.1% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09 , 0.13] 0.00 [-0.04 , 0.04]	M-H, Rando	
.2.1 Observational 999 Moller 002 Laasch 009 Galaski	PE Events 2 0 3	G Total 94 50 44	Ric Events 0 4	G Total 12 50 30	Weight 0.1% 0.4% 0.0%	M-H, Random, 95% Cl 0.02 [-0.09 , 0.13] 0.00 [-0.04 , 0.04] -0.07 [-0.21 , 0.08]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze	PE Events 2 0 3 1	G Total 94 50 44 97	Events 0 4 1	G Total 12 50 30 80	Weight 0.1% 0.4% 0.0% 0.6%	M-H, Random, 95% Cl 0.02 [-0.09 , 0.13] 0.00 [-0.04 , 0.04] -0.07 [-0.21 , 0.08] -0.00 [-0.03 , 0.03]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott	PE Events 2 0 3 1 3 3	G Total 94 50 44 97 121	Events 0 4 1 0	G Total 12 50 30 80 163	Weight 0.1% 0.4% 0.0% 0.6% 0.7%	M-H, Random, 95% Cl 0.02 [-0.09 , 0.13] 0.00 [-0.04 , 0.04] -0.07 [-0.21 , 0.08] -0.00 [-0.03 , 0.03] 0.02 [-0.01 , 0.06]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya	PE Events 2 0 3 1 3 0	G Total 94 50 44 97 121 52	RIC Events 0 0 4 1 0 2	G Total 12 50 30 80 163 86	Weight 0.1% 0.4% 0.0% 0.6% 0.7% 0.3%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park	PE Events 2 0 3 1 3 0 4	G Total 94 50 44 97 121 52 94	RIC Events 0 0 4 1 0 2 8	G Total 12 50 30 80 163 86 324	Weight 0.1% 0.4% 0.0% 0.6% 0.7% 0.3% 0.3%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park	PE Events 2 0 3 1 3 0	G Total 94 50 44 97 121 52	RIC Events 0 0 4 1 0 2	G Total 12 50 30 80 163 86	Weight 0.1% 0.4% 0.0% 0.6% 0.7% 0.3%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos	PE Events 2 0 3 1 3 0 4	G Total 94 50 44 97 121 52 94	RIC Events 0 0 4 1 0 2 8	G Total 12 50 30 80 163 86 324	Weight 0.1% 0.4% 0.0% 0.6% 0.7% 0.3% 0.3%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli	PE Events 2 0 3 1 3 0 4 6	G Total 94 50 44 97 121 52 94 469	RIC Events 0 0 4 1 0 2 8 6	G Total 12 50 30 80 163 86 324 291	Weight 0.1% 0.0% 0.6% 0.7% 0.3% 0.3% 1.6%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Park 019 Strijbos 020 Kohli 020 Lainez	PE Events 2 0 3 1 3 0 4 6 556	G Total 94 50 44 97 121 52 94 469 154007	RIC Events 0 0 4 1 0 2 8 6 29	G Total 12 50 30 163 86 324 291 16384	Weight 0.1% 0.6% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani	PE Events 2 0 3 1 3 0 4 6 556 1	G Total 94 50 44 97 121 52 94 469 154007 23	RIC Events 0 0 4 1 0 2 8 6 29 0	G Total 12 50 30 163 86 324 291 16384 25	Weight 0.1% 0.6% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli	PE Events 2 0 3 1 3 0 4 6 556 1 105	G Total 94 50 44 97 121 52 94 469 154007 23 26477	RIC Events 0 0 4 1 0 2 8 6 29 0 538	G Total 12 50 30 163 86 324 291 16384 25 232164	Weight 0.1% 0.6% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI)	PE Events 2 0 3 1 3 0 4 6 556 1 105	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715	RIC Events 0 0 4 1 0 2 8 6 29 0 538	G Total 12 50 30 80 163 86 324 291 16384 25 232164 23566	Weight 0.1% 0.6% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00]	M-H, Rando	
2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973	G Total 12 50 30 80 163 86 324 291 16384 25 232164 23566 273175	Weight 0.1% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Lainez 020 Maasarani 021 Kohli 022 Nasarani 021 Kohli 021 Kohli 022 Hohli 024 Kohli 025 Kohli 026 Kohli 027 Kohli 028 Kohli 029 Kohli 020 Kohli 021 Kohli 022 Kohli 023 Kohli 024 Kohli 025 Kohli 026 Kohli 027 Kohli 028 Kohli 029 Kohli 020 Kohl	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (<i>P</i>	G Total 12 50 30 80 163 86 324 291 16384 25 232164 23566 273175	Weight 0.1% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Lainez 020 Maasarani 021 Kohli 022 Nasarani 021 Kohli 021 Kohli 022 Hohli 024 Kohli 025 Kohli 026 Kohli 027 Kohli 028 Kohli 029 Kohli 020 Kohli 021 Kohli 022 Kohli 023 Kohli 024 Kohli 025 Kohli 026 Kohli 027 Kohli 028 Kohli 029 Kohli 020 Kohl	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (<i>P</i>	G Total 12 50 30 80 163 86 324 291 16384 25 232164 23566 273175	Weight 0.1% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%CI) otal events: eterogeneity: Tau ² = est for overall effect:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (<i>P</i>	G Total 12 50 30 80 163 86 324 291 16384 25 232164 23566 273175	Weight 0.1% 0.6% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events: eterogeneity: Tau ² = est for overall effect: 2.2 RCT	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 2 = 0.86)	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (<i>P</i>	G Total 12 50 30 80 163 86 324 291 16384 232164 23266 273175 < 0.0000	Weight 0.1% 0.4% 0.0% 0.7% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); I ² = 76	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events: eterogeneity: Tau ² = est for overall effect: 2.2 RCT 999 Hoffer	PEC Events 2 0 3 1 3 0 4 6 556 1 05 104 785 0.00; Chi ² Z = 0.18 (<i>F</i>	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 2 = 0.86)	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000	Weight 0.1% 0.4% 0.0% 0.6% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); I ² = 76 0.2%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] %	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%CI) otal events: eterogeneity: Tau ² = est for overall effect: 2.2 RCT 999 Hoffer 014 Lewis	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 2 = 0.86)	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (<i>P</i>	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000	Weight 0.1% 0.4% 0.0% 0.6% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l ² = 76 0.2% 0.2%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] -0.00 [-0.08, 0.02] 0.00 [-0.06, 0.06]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Kohli 021 Kohli 021 Kohli 021 Kohli 031 Kohli 032 Nasarani 031 Kohli 032 Nasarani 034 Kohli 035 Nototal (95%CI) otal events: eterogeneity: Tau ² = est for overall effect: .2.2 RCT 999 Hoffer 014 Lewis Subtotal (95%CI)	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 2 = 0.86)	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000	Weight 0.1% 0.4% 0.0% 0.6% 0.3% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); I ² = 76 0.2%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] %	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events: eterogeneity: Tau² = est for overall effect: .2.2 RCT 999 Hoffer 014 Lewis ubtotal (95% CI) otal events:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 = 0.86) 63 34 97	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 2 0 2 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2	G Total 12 50 30 80 163 86 324 291 16384 232164 23266 273175 < 0.0000 66 31 97	Weight 0.1% 0.4% 0.6% 0.7% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l ² = 76 0.2% 0.2% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] -0.00 [-0.08, 0.02] 0.00 [-0.06, 0.06]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events: eterogeneity: Tau² = est for overall effect: .2.2 RCT 999 Hoffer 014 Lewis ubtotal (95% CI) otal events: eterogeneity: Tau² =	PEC Events 2 0 3 1 3 0 4 6 556 1 005 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 = 0.86) 63 34 97 = 0.62, dt	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 2 0 2 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2	G Total 12 50 30 80 163 86 324 291 16384 232164 23266 273175 < 0.0000 66 31 97	Weight 0.1% 0.4% 0.6% 0.7% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l ² = 76 0.2% 0.2% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] -0.00 [-0.08, 0.02] 0.00 [-0.06, 0.06]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95% CI) otal events: eterogeneity: Tau² = est for overall effect: .2.2 RCT 999 Hoffer 014 Lewis ubtotal (95% CI) otal events: eterogeneity: Tau² =	PEC Events 2 0 3 1 3 0 4 6 556 1 005 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 = 0.86) 63 34 97 = 0.62, dt	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 2 0 2 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2	G Total 12 50 30 80 163 86 324 291 16384 232164 23266 273175 < 0.0000 66 31 97	Weight 0.1% 0.4% 0.6% 0.7% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l ² = 76 0.2% 0.2% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] -0.00 [-0.08, 0.02] 0.00 [-0.06, 0.06]	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%CI) otal events: eterogeneity: Tau ² = est for overall effect: 2.2 RCT 999 Hoffer 014 Lewis ubtotal (95%CI) otal events: eterogeneity: Tau ² = est for overall effect:	PEC Events 2 0 3 1 3 0 4 6 556 1 005 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0 0.00; Chi ²	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (*) = 0.86) 63 34 97 = 0.62, (*)	Ric Events 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 2 0 2 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2	G Total 12 50 30 80 163 86 324 291 16384 23566 273175 < 0.0000 66 31 97 0.43); l ² =	Weight 0.1% 0.4% 0.0% 0.7% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); ² = 76 0.2% 0.2% 0.2% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] 0.04 [-0.07, 0.15] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] % %	M-H, Rando	
tudy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%CI) otal events: eterogeneity: Tau² = est for overall effect: 2.2 RCT 999 Hoffer 014 Lewis ubtotal (95%CI) otal events: eterogeneity: Tau² = est for overall effect: otal events: eterogeneity: Tau² = est for overall (95%CI) otal events: eterogeneity: Tau² = est for overall effect:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0.00; Chi ² Z = 0.89 (A	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (2 = 0.86) 63 34 97 = 0.62, dt	Rife Events $ \begin{array}{c} 0 \\ 0 \\ 4 \\ 1 \\ 0 \\ 2 \\ 8 \\ 6 \\ 29 \\ 0 \\ 538 \\ 385 \\ 973 \\ df = 11 (P \\ 2 \\ 0 \\ c \\ c$	G Total 12 50 30 80 163 86 324 291 16384 23566 273175 < 0.0000 66 31 97 0.43); l ² =	Weight 0.1% 0.4% 0.6% 0.7% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l ² = 76 0.2% 0.2% 0.4%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.00, 0.00] -0.00 [-0.00, 0.00] -0.00 [-0.08, 0.02] 0.00 [-0.06, 0.06]	M-H, Rando	
Ludy or Subgroup 2.1 Observational 299 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Lainez 020 Maasarani 021 Kohli 020 Lainez 020 Maasarani 021 Kohli 020 Lainez 020 Maasarani 021 Kohli 024 Rottl 035% CI) 044 Lewis 045 Hoffer 014 Lewis ubtotal (95% CI) 04a events: eterogeneity: Tau ² = est for overall effect: 04a events: eterogeneity: Tau ² = est for overall effect: 04al events:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0.00; Chi ² Z = 0.89 (A 785)	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (7 = 0.86) 63 34 97 = 0.62, dt 2 = 0.37) 191340	Rivents 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 f = 1 (P = 975	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000 66 31 97 0.43); l ² = 273272	Weight 0.1% 0.4% 0.0% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l² = 76 0.2% 0.2% 0.4% 0.4% 0.2% 0.4% 100.0%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.02] 0.00 [-0.06, 0.02] -0.02 [-0.06, 0.02] -0.00 [-0.00, 0.00]	M-H, Rando	
Ludy or Subgroup 2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%Cl) otal events: eterogeneity: Tau² = est for overall effect: 2.2 RCT 999 Hoffer 014 Lewis ubtotal (95%Cl) otal events: eterogeneity: Tau² = est for overall effect: otal events: eterogeneity: Tau² = est for overall effect: otal events: eterogeneity: Tau² = est for overall effect: otal events: otal events:	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0.00; Chi ² Z = 0.89 (A 785)	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (7 = 0.86) 63 34 97 = 0.62, dt 2 = 0.37) 191340	Rivents 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 f = 1 (P = 975	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000 66 31 97 0.43); l ² = 273272	Weight 0.1% 0.4% 0.0% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); l² = 76 0.2% 0.2% 0.4% 0.4% 0.2% 0.4% 100.0%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.02] 0.00 [-0.06, 0.02] -0.02 [-0.06, 0.02] -0.00 [-0.00, 0.00]	M-H, Rando	
tudy or Subgroup .2.1 Observational 999 Moller 002 Laasch 009 Galaski 012 La Nauze 015 McDermott 018 Vidhya 019 Park 019 Strijbos 020 Kohli 020 Lainez 020 Maasarani 021 Kohli ubtotal (95%Cl) otal events: leterogeneity: Tau ² = est for overall effect: .2.2 RCT 999 Hoffer 014 Lewis ubtotal (95%Cl)	PE Events 2 0 3 1 3 0 4 6 556 1 105 104 785 0.00; Chi ² Z = 0.18 (A 0 0 0 0 0 0.00; Chi ² Z = 0.89 (A 785 0.00; Chi ² C = 0.89	G Total 94 50 44 97 121 52 94 469 154007 23 26477 9715 191243 = 46.69, (= 0.86) 63 34 97 = 0.62, dt 2 = 0.37) 191340 = 48.69, (Rivents 0 0 4 1 0 2 8 6 29 0 538 385 973 df = 11 (P 2 0 f = 1 (P = 975	G Total 12 50 30 80 163 86 324 291 16384 232164 23566 273175 < 0.0000 66 31 97 0.43); l ² = 273272	Weight 0.1% 0.4% 0.0% 0.3% 1.6% 34.9% 0.1% 34.7% 25.9% 99.6% 1); I² = 76 0.2% 0.2% 0.4% 0.4% 0.2% 0.4% 100.0%	M-H, Random, 95% Cl 0.02 [-0.09, 0.13] 0.00 [-0.04, 0.04] -0.07 [-0.21, 0.08] -0.00 [-0.03, 0.03] 0.02 [-0.01, 0.06] -0.02 [-0.07, 0.02] 0.02 [-0.03, 0.06] -0.01 [-0.03, 0.01] 0.00 [0.00, 0.00] -0.01 [-0.01, -0.00] -0.01 [-0.01, -0.00] -0.00 [-0.00, 0.02] 0.00 [-0.06, 0.02] -0.02 [-0.06, 0.02] -0.00 [-0.00, 0.00]	M-H, Rando	m, 95%Cl

Test for subgroup differences: $Chi^2 = 0.78$, df = 1 (P = 0.38), $I^2 = 0\%$



С	RIG	G	PE	G		Risk difference (Non-event)) Risk difference (Non-event)
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.3.1 Observational							
2002 Laasch	0	50	5	50	2.7%	0.10 [0.01 , 0.19	91
2012 La Nauze	4	97	4	80	5.6%	0.01 [-0.05 , 0.07	•
2015 McDermott	4	121	4	163	13.5%	-0.01 [-0.05 , 0.03	·
2018 Vidhya	0	52	2	85	11.0%	0.02 [-0.02 , 0.07	
2019 Strijbos	4	469	6	291	63.7%	0.01 [-0.01 , 0.03	31
2020 Lainez	0	23	2	25	1.3%	0.08 [-0.05 , 0.21	· _
Subtotal (95% CI)		812		694	97.9%	0.02 [-0.00 , 0.04	
Total events:	12		23			• •	· •
Heterogeneity: Tau ² =	0.00; Chi ²	= 6.28, d	f = 5 (<i>P</i> =	0.28); l² =	20%		
Test for overall effect:							
1.3.2 RCT							
1999 Hoffer	13	66	11	69	1.3%	-0.04 [-0.17 , 0.09	
2014 Lewis	3	31	5	34	0.9%	0.05 [-0.11 , 0.21	•
Subtotal (95%CI)	0	97	0	103	2.1%	-0.00 [-0.10 , 0.10	
Total events:	16		16	100	2.170	-0.00 [-0.10 , 0.10	
Heterogeneity: Tau ² =		= 0.73 dt		0.39)· I ² =	0%		
Test for overall effect:				0.00), 1	0,0		
Total (95% CI)		909		797	100.0%	0.01 [-0.00 , 0.03	3]
Total events:	28		39			•	- \
Heterogeneity: Tau ² =	0.00; Chi ²	= 6.90, di	f = 7 (<i>P</i> =	0.44); I² =	0%		-0.1 -0.05 0 0.05 0.
Test for overall effect:	Z = 1.79 (A	P = 0.07)					Favours (PEG) Favours (RIG
Test for subgroup diffe	erences: Ch	ni² = 0.12,	df = 1 (<i>P</i>	= 0.73), l ⁱ	² = 0%		
D	RI	G	PE	G		Risk difference	Risk difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1999 Moller	1	94	0	12	2.3%	0.01 [-0.10 , 0.12]	
2012 La Nauze	1	97	0	80	17.3%	0.01 [-0.02, 0.04]	
2018 Vidhya	1	52	2	85	8.9%	-0.00 [-0.05 , 0.05]	
2019 Strijbos	2	469	0	291	34.4%	0.00 [-0.00 , 0.01]	_
2021 Kohli	23	9715	453	23566	37.1%	-0.02 [-0.02 , -0.01]	•
Total (95%CI)		10427		24034	100.0%	-0.00 [-0.02 , 0.01]	
Total events:	28		455			,,	Ţ
Heterogeneity: Tau ² =		= 28.23.		< 0.0001)	: I² = 86%	-	-0.2 -0.1 0 0.1 0.2
Test for overall effect:	-		•				avours (RIG) Favours (PEG)
Test for subgroup diffe							
E	RI	G	PE	G		Risk difference (Non-event) Risk difference (Non-event)

E	RIG		PE	G		Risk difference (Non-event)	Risk difference (Non-event)
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95%Cl
2005 Silas	6	193	4	177	17.7%	-0.01 [-0.04 , 0.02]	
2010 Rio	36	122	5	21	2.7%	-0.06 [-0.26 , 0.14]	· · · · · · · · · · · · · · · · · · ·
2012 La Nauze	5	97	5	80	11.5%	0.01 [-0.06 , 0.08]	_ - _
2015 McDermott	34	121	25	163	7.9%	-0.13 [-0.22 , -0.03]	
2019 Park	0	94	7	324	19.4%	0.02 [-0.00 , 0.04]	
2019 Strijbos	7	469	5	291	19.9%	0.00 [-0.02 , 0.02]	+
2020 Maasarani	12142	26477	96154	232164	20.9%	-0.04 [-0.05 , -0.04]	•
Total (95% CI)		27573		233220	100.0%	-0.02 [-0.05 , 0.02]	•
Total events:	12230		96205				
Heterogeneity: Tau ² =	0.00; Chi ²	= 68.06,	df = 6 (<i>P</i> •	< 0.00001); I² = 91%	6	-0.2 -0.1 0 0.1 0.2
Test for overall effect:	Z = 0.93 (/	P = 0.35)					Favours (PEG) Favours (RIG)
Test for subgroup diffe	erences: No	ot applica	ble				

DOI: 10.13105/wjma.v11.i6.277 Copyright ©The Author(s) 2023.

Figure 5 Forest plot studies reporting. A: Outcomes infection; B: Outcomes bleeding; C: Pneumonia; D: Outcomes peritonitis; E: Pain.

comparison. Additionally, we separated all adverse events, including pain and pneumonia, which have not been individually analyzed to date. The adverse effects chosen were based on previous publications showing the most frequent complications related to the method[4].

The three most common techniques for performing gastrostomy are endoscopic, radiologic, and surgical. Although surgical gastrostomy was the first described approach, it is now less used due to its invasiveness. A meta-analysis including RCT (evidence 1A) comparing endoscopic and surgical techniques demonstrated a lower number of minor complications for endoscopic procedures[35].

Until now, there is no consensus regarding the superiority of either endoscopic or radiologic gastrostomy. Our results clarify that both approaches are similar in terms of safety as shown in our meta-analysis including only RCTs.

Raisbideng® WJMA https://www.wjgnet.com

	RI	G	PE	G		Risk difference (Non-event)	Risk difference (Non-event)		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95%Cl		
1.5.1 Observational									
1999 Moller	5	94	0	12	2.8%	-0.05 [-0.17 , 0.06]			
2002 Laasch	2	50	6	50	3.2%	0.08 [-0.03 , 0.19]			
2005 Silas	10	193	4	177	10.7%	-0.03 [-0.07 , 0.01]			
2006 Rustom	6	28	2	40	1.5%	-0.16 [-0.33 , 0.00]	←		
2009 Galaski	2	44	2	30	3.1%	0.02 [-0.09 , 0.13]			
2010 Rio	2	21	7	122	2.2%	-0.04 [-0.17 , 0.09]			
2018 Vidhya	14	52	2	85	2.4%	-0.25 [-0.37 , -0.12]	←─── │		
2019 Park	15	94	19	324	5.0%	-0.10 [-0.18 , -0.02]			
2019 Strijbos	124	469	8	291	9.6%	-0.24 [-0.28 , -0.19]	←		
2020 Kohli	4149	154007	459	16384	16.5%	0.00 [-0.00 , 0.00]			
2020 Maasarani	1496	26477	5459	232164	16.5%	-0.03 [-0.04 , -0.03]			
2021 Kohli	864	9715	1538	23566	16.3%	-0.02 [-0.03 , -0.02]	-		
Subtotal (95%CI)		191244		273245	89.7%	-0.05 [-0.08 , -0.03]	▲		
Total events:	6689		7506				•		
Heterogeneity: Tau ² =	0.00; Chi ²	= 458.08	, df = 11 (/	P < 0.000	01); I ² = §	98%			
est for overall effect:			-						
.5.2 RCT									
1999 Hoffer	2	66	1	69	8.5%	-0.02 [-0.07 , 0.03]			
2012 La Nauze	2	31	5	34	1.8%	0.08 [-0.06 , 0.23]			
Subtotal (95%CI)		97		103	10.3%	0.02 [-0.10 , 0.13]			
otal events:	4		6						
Heterogeneity: Tau ² =	0.00; Chi ²	= 2.35, d	f = 1 (<i>P</i> =	0.13); l² =	= 57%				
Test for overall effect:	Z = 0.29 (/	P = 0.77)							
Total (95% CI)		191341		273348	100.0%	-0.05 [-0.07 , -0.03]	•		
Total events:	6693		7512				•		
Heterogeneity: Tau ² =	0.00; Chi ²	= 459.54	, df = 13 (<i>i</i>	P < 0.000	01); l² = 9	97%	-0.2 -0.1 0 0.1 0.2		
Test for overall effect:	Z = 4.41 (/	P < 0.000)1)				Favours (PEG) Favours (RIC		
est for subgroup diffe	erences: Cl	hi² = 1.43	, df = 1 (<i>P</i>	= 0.23),	² = 29.9%	Ď	· · · ·		
					DOI	: 10.13105/wjma.v11.i6.277	Copyright ©The Author(s) 2023.		

Figure 6 Forest plot with studies reporting tube related complications.

Furthermore, a recent RCT including 42 patients comparing the two techniques[36], showed similar results to this metaanalysis. Unfortunately, this RCT was not included due to a lack of data available in the published manuscript, despite our attempt to contact the author.

Local infection is a common adverse outcome of gastrostomy. For this reason, the American Society for Gastrointestinal Endoscopy[37] and the Society for Interventional Radiology [38,39] recommends administering periprocedural antibiotics. The studies utilized in this meta-analysis did not expressly state if antibiotics were administered or not, but as this is a common practice, it was likely used. Our meta-analysis did not demonstrate a significant difference regarding infection in both RCT and non-RCT analysis.

In previous publications [26,27], it has been stated that patients undergoing PEG have a higher rate of bleeding since PEG is preferentially performed in patients with diseases requiring antiplatelets or anticoagulants such as stroke and vascular dementia[27,40]. We expected to prove this hypothesis, however, this meta-analysis demonstrated a low risk of bleeding due to the gastrostomy procedure, without a statistically significant difference between PEG and PRG in both RCT and observational studies. Data on antiplatelet and/or anticoagulant medications among patients who bled were not available.

This study showed no significant difference in the incidence of pneumonia. In previous studies it was observed that gastrostomy compared to nasogastric feeding has a lower incidence of pneumonia, however, this complication is a major cause of mortality in patients undergoing gastrostomy [16]. It is important to state that we were not able to evaluate gastrostomy and gastrojejunostomy separately due to a lack of data. Gastrojejunostomy is associated with a theoretically lower rate of reflux and pneumonia[11,19].

Pain and peritonitis are complex outcomes to measure objectively. Since the definition of these outcomes differs in several studies[13,14,17,18,20-25]. There was no statistical difference between the two methods in our study.

In the analyzed studies, the types, brands, and sizes of tubes were not differentiated. This heterogeneity may influence the results of this analysis. The meta-analysis of observational studies demonstrated a statistically significant difference in the incidence of tube-related complications of a PEG and PRG, such as dislocation, leak, obstruction, or breakdown, showing a higher incidence in PRG. In the RCT meta-analysis, there was no difference. However, the observational studies included 464489 patients versus 200 patients from RCT studies and this should be considered if the RCTs were underpowered to detect a small difference between the techniques. A difference may be expected due to the size difference between endoscopic and radiological techniques. PEG is usually performed using 20FR or 24FR tubes whereas PRG uses 14-16 FR[41]. The size of the gastrostomy ostium influences the incidence of migration; a smaller caliber is associated with a higher incidence of migration and obstruction. The feeding tube can become blocked due to various



WJMA https://www.wjgnet.com

reasons, such as the accumulation of food formula, medications, or debris. Smaller tubes increase the probability of the tube becoming blocked. Leaks can occur around the insertion site or through the tube itself, which can cause skin irritation and infection, so if the size of the skin insertion is larger than the tube caliber there is a greater chance of leakage.

Tube-related complications are usually associated with longer hospital stays, the need for further procedures, and potentially increased costs[16,33,42]. Evaluating costs is challenging since procedure cost varies significantly between countries. A study comparing the two techniques published in 2009 showed that the costs of the procedures are also different, with PEGs being 43% more expensive than PRGs[16] but the costs are related only to the procedure and not to the overall cost. In Brazil, PEG has a low cost, being more cost-effective than a CT scan. Although few studies provide information regarding costs, this information would be useful, given that these procedures are performed on a large scale worldwide[11,16].

The strengths of this study include a large number of patients from different continents, dedicated analysis of RCT data, use of a validated quality assessment tool, and application of the GRADE process to assess the quality of our data.

Although systematic review and meta-analysis represent the most thorough assessment of available evidence comparing the risks of PEG and PRG, our study has limitations as discussed above. Most data was gathered from observational studies. Additionally, lack of data on tube size, antibiotic, and anticoagulant use, indications for the gastrostomy procedure, and inclusion of both gastrostomy and gastrojejunostomy all limit understanding of potential nuances that differentiate PEG from PRG.

In summary, both approaches are safe. Thus, individual evaluation is required considering several factors including local and personal experience, device availability, cost, and patient preference.

CONCLUSION

PEG and PRG present a similar safety profile. However, PRG is associated with a slightly higher rate of tube-related complications, potentially related to the small caliber of the gastrostomy tube.

ARTICLE HIGHLIGHTS

Research background

Gastrostomy feeding is superior to nasogastric tube feeding when medium to long-term enteral feeding (≥ 4 wk) is indicated. The optimal technique for long-term enteral feeding is not yet well established. Therefore, we performed a meta-analysis comparing the two methods.

Research motivation

This paper motivation is to demonstrate which technique for performing a gastrostomy has the lowest incidence rate of adverse events.

Research objectives

The aim of the paper is to compare the technique of endoscopic gastrostomy (PEG) and gastrostomy via interventional radiology (PRG) and establish which technique is the safest for the patient.

Research methods

Comparative studies of PEG and PRG were selected. Included studies had outcomes such as infection, bleeding, pneumonia, pain, peritonitis and tube related complications. The risk of bias and quality of evidence were assessed. The analysis was performed using Review Manager (RevMan 5.4) from the Cochrane Informatics & Knowledge Management Department website.

Research results

Seventeen studies were included, with a total of 465218 patients. The only outcome that showed a significant difference was tube-related complications in retrospective studies favoring PEG (95% CI: 0.03 to 0.08; P < 0.00001), although this outcome did not show significant difference in randomized studies (95%CI: -0.07 to 0.04; P = 0.13). There was no difference in the analyses of the following outcomes: Infection in retrospective (95%CI: -0.01 to 0.00; P < 0.00001) or randomized (95%CI: -0.06 to 0.04; P = 0.44) studies; bleeding in retrospective (95%CI: -0.00 to 0.00; P < 0.00001) or randomized (95%CI: -0.06 to 0.02; P = 0.43) studies; pneumonia in retrospective (95%CI: -0.04 to 0.00; P = 0.28) or randomized (95%CI: -0.09 to 0.11; P = 0.39) studies; pain in retrospective (95%CI: -0.05 to 0.02; P < 0.00001) studies; peritonitis in retrospective (95%CI: -0.02 to 0.01; *P* < 0.0001) studies.

Research conclusions

The study concluded that RIG has a higher incidence of tube-related complications than PEG. This difference is probably associated with the caliber of the tubes used. There was no statistical difference in the other outcomes evaluated.



WJMA https://www.wjgnet.com

Research perspectives

This study aimed to determine which technique is safer for the patient, and both methods proved to be safe. We can conclude that the choice of technique depends on the type of patient, the experience of the service, the cost, and the availability of the method.

FOOTNOTES

Author contributions: dos Santos ESV contributed acquisition of data, analysis, interpretation of data, drafting the article, revising the article, final approval; de Oliveira GHP, dos Santos ESV and Hirsch BS contributed analysis and interpretation of data, revising the article; de Moura DTH contributed analysis of data, interpretation of data, drafting the article, revising the article, final approval; Bernardo WM contributed analysis of data, interpretation of data, drafting the article, revising the article, final approval; de Moura EGH contributed analysis and interpretation of data, drafting the article, revising the article, final approval.

Conflict-of-interest statement: The authors deny any conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Brazil

ORCID number: Guilherme Henrique Peixoto de Oliveira 0000-0002-1057-2390; Diogo Turiani Hourneaux de Moura 0000-0002-7446-0355; Bruno Salomão Hirsch 0000-0002-0777-0150; Roberto Paolo Trasolini 0000-0001-8059-9807; Wanderley Marques Bernardo 0000-0002-8597-5207; Eduardo Guimarães Hourneaux de Moura 0000-0003-1215-5731.

S-Editor: Liu JH L-Editor: A P-Editor: Zhao S

REFERENCES

- Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better 1 outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 2004; 20: 843-848 [PMID: 15474870 DOI: 10.1016/j.nut.2004.06.003
- Gauderer MW, Ponsky JL, Izant RJ Jr. Gastrostomy without laparotomy: a percutaneous endoscopic technique. J Pediatr Surg 1980; 15: 872-2 875 [PMID: 6780678 DOI: 10.1016/S0022-3468(80)80296-X]
- 3 Preshaw RM. A percutaneous method for inserting a feeding gastrostomy tube. Surg Gynecol Obstet 1981; 152: 658-660 [PMID: 6784260]
- Rahnemai-Azar AA, Rahnemaiazar AA, Naghshizadian R, Kurtz A, Farkas DT. Percutaneous endoscopic gastrostomy: indications, technique, 4 complications and management. World J Gastroenterol 2014; 20: 7739-7751 [PMID: 24976711 DOI: 10.3748/wjg.v20.i24.7739]
- Leeds JS, McAlindon ME, Grant J, Robson HE, Lee FK, Sanders DS. Survival analysis after gastrostomy: a single-centre, observational study 5 comparing radiological and endoscopic insertion. Eur J Gastroenterol Hepatol 2010; 22: 591-596 [PMID: 19966570 DOI: 10.1097/MEG.0b013e328332d2dd
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the 6 PRISMA statement. PLoS Med 2009; 6: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]
- Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, 7 Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919 [PMID: 27733354 DOI: 10.1136/bmj.i4919]
- 8 Cochrane HandbookforSystematicReviewsofInterventionsversion6.0 Internet]. London (UK); c2019 [Cited 2021 Apr 16]. Available from: https://training.cochrane.org/handbook
- 9 Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926 [PMID: 18436948 DOI: 10.1136/bmj.39489.470347.AD]
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 10 2005; 5: 13 [PMID: 15840177 DOI: 10.1186/1471-2288-5-13]
- 11 Hoffer EK, Cosgrove JM, Levin DQ, Herskowitz MM, Sclafani SJ. Radiologic gastrojejunostomy and percutaneous endoscopic gastrostomy: a prospective, randomized comparison. J Vasc Interv Radiol 1999; 10: 413-420 [PMID: 10229468 DOI: 10.1016/S1051-0443(99)70058-8]
- Möller P, Lindberg CG, Zilling T. Gastrostomy by various techniques: evaluation of indications, outcome, and complications. Scand J 12 Gastroenterol 1999; 34: 1050-1054 [PMID: 10563677 DOI: 10.1080/003655299750025174]



- Laasch HU, Wilbraham L, Bullen K, Marriott A, Lawrance JA, Johnson RJ, Lee SH, England RE, Gamble GE, Martin DF. Gastrostomy 13 insertion: comparing the options--PEG, RIG or PIG? Clin Radiol 2003; 58: 398-405 [PMID: 12727170 DOI: 10.1016/S0009-9260(03)00058-8]
- 14 Silas AM, Pearce LF, Lestina LS, Grove MR, Tosteson A, Manganiello WD, Bettmann MA, Gordon SR. Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients. Eur J Radiol 2005; 56: 84-90 [PMID: 16168268 DOI: 10.1016/j.ejrad.2005.02.007]
- Rustom IK, Jebreel A, Tayyab M, England RJ, Stafford ND. Percutaneous endoscopic, radiological and surgical gastrostomy tubes: a 15 comparison study in head and neck cancer patients. J Laryngol Otol 2006; 120: 463-466 [PMID: 16772054 DOI: 10.1017/S0022215106000661]
- 16 Galaski A, Peng WW, Ellis M, Darling P, Common A, Tucker E. Gastrostomy tube placement by radiological versus endoscopic methods in an acute care setting: a retrospective review of frequency, indications, complications and outcomes. Can J Gastroenterol 2009; 23: 109-114 [PMID: 19214286 DOI: 10.1155/2009/801925]
- 17 La Nauze RJ, Collins K, Lyon S, Bailey M, Kemp W, Nyulasi I, Roberts SK. Outcomes of percutaneous endoscopic gastrostomy vs radiologically inserted gastrostomy tube insertion at a tertiary hospital. e-SPEN J 2012; 7: e144-e148 [DOI: 10.1016/j.clnme.2012.05.001]
- Rio A, Ellis C, Shaw C, Willey E, Ampong MA, Wijesekera L, Rittman T, Nigel Leigh P, Sidhu PS, Al-Chalabi A. Nutritional factors 18 associated with survival following enteral tube feeding in patients with motor neurone disease. J Hum Nutr Diet 2010; 23: 408-415 [PMID: 20487174 DOI: 10.1111/j.1365-277X.2010.01057.x]
- Lewis S, Jackson S, Latchford A. Randomized Study of Radiologic vs Endoscopic Placement of Gastrojejunostomies in Patients at Risk of 19 Aspiration Pneumonia. Nutr Clin Pract 2014; 29: 498-503 [PMID: 24759762 DOI: 10.1177/0884533614529999]
- ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol 2015; 20 14: 702-709 [PMID: 26027943 DOI: 10.1016/S1474-4422(15)00104-0]
- 21 Vidhya C, Phoebe D, Dhina C, Jayne S, Robert F. Percutaneous endoscopic gastrostomy (PEG) versus radiologically inserted gastrostomy (RIG): A comparison of outcomes at an Australian teaching hospital. Clin Nutr ESPEN 2018; 23: 136-140 [PMID: 29460789 DOI: 10.1016/j.clnesp.2017.10.014]
- Park SK, Kim JY, Koh SJ, Lee YJ, Jang HJ, Park SJ; Small Intestine and Nutrition Research Group of the Korean Association for the Study of 22 Intestinal Diseases (KASID). Complications of percutaneous endoscopic and radiologic gastrostomy tube insertion: a KASID (Korean Association for the Study of Intestinal Diseases) study. Surg Endosc 2019; 33: 750-756 [PMID: 30132209 DOI: 10.1007/s00464-018-6339-1]
- Strijbos D, Keszthelyi D, Gilissen LPL, Lacko M, Hoeijmakers JGJ, van der Leij C, de Ridder RJJ, de Haan MW, Masclee AAM. 23 Percutaneous endoscopic versus radiologic gastrostomy for enteral feeding: a retrospective analysis on outcomes and complications. Endosc Int Open 2019; 7: E1487-E1495 [PMID: 31673622 DOI: 10.1055/a-0953-1524]
- Lainez LM, Florencio Ojeda L, Ternero Fonseca J, Maraver Zamora M, Rebollo P, M. I. Percutaneous endoscopic gastrostomy (PEG) vs 24 radiologic percutaneous gastrostomy (RPG): comparison of the results in our center in the last year. Clinical Nutrition ESPEN, 2020; 40: 678 [DOI: 10.1016/j.clnesp.2020.09.822]
- Maasarani S, Khalid SI, Creighton C, Manatis-Lornell AJ, Wiegmann AL, Terranella SL, Skertich NJ, DeCesare L, Chan EY. Outcomes 25 following percutaneous endoscopic gastrostomy versus fluoroscopic procedures in the Medicare population. Surg Open Sci 2021; 3: 2-7 [PMID: 33937737 DOI: 10.1016/j.sopen.2020.06.001]
- Kohli DR, Kennedy KF, Desai M, Sharma P. Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical 26 gastrostomy: nationwide inpatient assessment. Gastrointest Endosc 2021; 93: 1077-1085.e1 [PMID: 32931781 DOI: 10.1016/j.gie.2020.09.012]
- Kohli DR, Kennedy KF, Desai M, Sharma P. Comparative Safety of Endoscopic vs Radiological Gastrostomy Tube Placement: Outcomes 27 From a Large, Nationwide Veterans Affairs Database. Am J Gastroenterol 2021; 116: 2367-2373 [PMID: 34506328 DOI: 10.14309/ajg.000000000001504]
- Bravo JG, Ide E, Kondo A, de Moura DT, de Moura ET, Sakai P, Bernardo WM, de Moura EG. Percutaneous endoscopic versus surgical 28 gastrostomy in patients with benign and malignant diseases: a systematic review and meta-analysis. Clinics (Sao Paulo) 2016; 71: 169-178 [PMID: 27074179 DOI: 10.6061/clinics/2016(03)09]
- Strijbos D, Keszthelyi D, Bogie RMM, Gilissen LPL, Lacko M, Hoeijmakers JGJ, van der Leij C, de Ridder R, de Haan MW, Masclee AAM. 29 A Systematic Review and Meta-Analysis on Outcomes and Complications of Percutaneous Endoscopic Versus Radiologic Gastrostomy for Enteral Feeding. J Clin Gastroenterol 2018; 52: 753-764 [PMID: 29924079 DOI: 10.1097/MCG.000000000001082]
- Mohamed Elfadil O, Linch FB, Seegmiller SL, Hurt RT, Mundi MS, Neisen MJ. Safety and effectiveness of radiologic and endoscopic 30 percutaneous gastrostomy placement: A randomized study. JPEN J Parenter Enteral Nutr 2022; 46: 1808-1817 [PMID: 35428993 DOI: 10.1002/jpen.2365]
- Wollman B, D'Agostino HB, Walus-Wigle JR, Easter DW, Beale A. Radiologic, endoscopic, and surgical gastrostomy: an institutional 31 evaluation and meta-analysis of the literature. Radiology 1995; 197: 699-704 [PMID: 7480742 DOI: 10.1148/radiology.197.3.7480742]
- Grant DG, Bradley PT, Pothier DD, Bailey D, Caldera S, Baldwin DL, Birchall MA. Complications following gastrostomy tube insertion in 32 patients with head and neck cancer: a prospective multi-institution study, systematic review and meta-analysis. Clin Otolaryngol 2009; 34: 103-112 [PMID: 19413607 DOI: 10.1111/j.1749-4486.2009.01889.x]
- Burkitt P, Carter LM, Smith AB, Kanatas A. Outcomes of percutaneous endoscopic gastrostomy and radiologically inserted gastrostomy in 33 patients with head and neck cancer: a systematic review. Br J Oral Maxillofac Surg 2011; 49: 516-520 [PMID: 20952109 DOI: 10.1016/j.bjoms.2010.09.005]
- 34 Yuan TW, He Y, Wang SB, Kong P, Cao J. Technical success rate and safety of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy in motor neuron disease patients undergoing: A systematic review and meta-analysis. J Neurol Sci 2020; 410: 116622 [PMID: 31884351 DOI: 10.1016/j.jns.2019.116622]
- Yang B, Shi X. Percutaneous endoscopic gastrostomy versus fluoroscopic gastrostomy in amyotrophic lateral sclerosis (ALS) sufferers with 35 nutritional impairment: A meta-analysis of current studies. Oncotarget 2017; 8: 102244-102253 [PMID: 29254240 DOI: 10.18632/oncotarget.22288]
- Lim JH, Choi SH, Lee C, Seo JY, Kang HY, Yang JI, Chung SJ, Kim JS. Thirty-day mortality after percutaneous gastrostomy by endoscopic 36 versus radiologic placement: a systematic review and meta-analysis. Intest Res 2016; 14: 333-342 [PMID: 27799884 DOI: 10.5217/ir.2016.14.4.333]
- ASGE Standards of Practice Committee, Khashab MA, Chithadi KV, Acosta RD, Bruining DH, Chandrasekhara V, Eloubeidi MA, Fanelli 37 RD, Faulx AL, Fonkalsrud L, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Shaukat A, Wang A, Cash BD. Antibiotic prophylaxis for



GI endoscopy. Gastrointest Endosc 2015; 81: 81-89 [PMID: 25442089 DOI: 10.1016/j.gie.2014.08.008]

- Itkin M, DeLegge MH, Fang JC, McClave SA, Kundu S, d'Othee BJ, Martinez-Salazar GM, Sacks D, Swan TL, Towbin RB, Walker TG, 38 Wojak JC, Zuckerman DA, Cardella JF; Society of Interventional Radiology; American Gastroenterological Association Institute; Canadian Interventional Radiological Association; Cardiovascular and Interventional Radiological Society of Europe. Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, with endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Gastroenterology 2011; 141: 742-765 [PMID: 21820533 DOI: 10.1053/j.gastro.2011.06.001]
- 39 Chehab MA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM, Ward TJ, Padia SA, Kohi MP, Midia M, Chaudry G, Gemmete JJ, Mitchell JW, Brody L, Crowley JJ, Heran MKS, Weinstein JL, Nikolic B, Dariushnia SR, Tam AL, Venkatesan AM. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol 2018; 29: 1483-1501.e2 [PMID: 30274857 DOI: 10.1016/j.jvir.2018.06.007]
- Azzopardi N, Ellul P. Pneumonia and mortality after percutaneous endoscopic gastrostomy insertion. Turk J Gastroenterol 2013; 24: 109-116 40 [PMID: 23934456 DOI: 10.4318/tjg.2013.0512]
- Shin JH, Park AW. Updates on percutaneous radiologic gastrostomy/gastrojejunostomy and jejunostomy. Gut Liver 2010; 4 Suppl 1: S25-S31 41 [PMID: 21103291 DOI: 10.5009/gnl.2010.4.S1.S25]
- Barkmeier JM, Trerotola SO, Wiebke EA, Sherman S, Harris VJ, Snidow JJ, Johnson MS, Rogers WJ, Zhou XH. Percutaneous radiologic, 42 surgical endoscopic, and percutaneous endoscopic gastrostomy/gastrojejunostomy: comparative study and cost analysis. Cardiovasc Intervent Radiol 1998; 21: 324-328 [PMID: 9688801 DOI: 10.1007/s002709900269]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

